Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes

Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes

Abstract Imeglimin is an orally administered first‐in‐class drug to treat type 2 diabetes mellitus (T2DM) and is mainly excreted unchanged by the kidneys. The present study aimed to define the pharmacokinetic (PK) characteristics of imeglimin using population PK analysis and to determine the optimal...

Full description

Bibliographic Details
Main Authors: Yoshiko Tomita, Emma Hansson, Florent Mazuir, Gustaf J Wellhagen, Qing Xi Ooi, Enrica Mezzalana, Atsushi Kitamura, Daisuke Nemoto, Sébastien Bolze
Format: Article
Language:English
Published: Wiley 2022-04-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.13221

Internet

https://doi.org/10.1111/cts.13221

Similar Items